Renalytix plc Issue of shares
April 08 2022 - 7:00AM
Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the
Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new
ordinary shares of £0.0025 each in the capital of the Company (the
"Ordinary Shares") have been issued to settle the purchase of
11,407 American Depositary Shares, each representing two Ordinary
Shares, by employees who participated in the ESPP. This was
carried out at a subscription price of $7.8795 per American
Depositary Share (£3.00 per Ordinary Share). Further details in
relation to the ESPP were contained in the Company's announcement
of 2 September 2020.
An application has been made to the London Stock
Exchange for the new Ordinary Shares to be admitted to trading on
AIM. It is expected that admission of the 22,814 new Ordinary
Shares to trading on AIM will become effective on, or around, 12
April 2022 ("Admission").
Total voting rightsFollowing
Admission, the Company will have 74,760,432 Ordinary Shares in
issue with each share carrying the right to one vote. The Company
has no Ordinary Shares held in treasury. The total number of voting
rights in the Company following Admission will therefore be
74,760,432.
For further information, please contact:
Renalytix plc |
www.renalytix.com |
James McCullough, CEO |
Via Walbrook PR |
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
Alex Price / Nicholas Moore |
|
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
Gary Clarence / Daniel Adams |
|
|
|
Walbrook PR Limited |
Tel: 020 7933
8780 or renalytix@walbrookpr.com |
Paul McManus / Lianne Applegarth / Alice Woodings |
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|
|
CapComm Partners |
Tel:
415-389-6400 or investors@renalytix.com |
Peter DeNardo |
|
About RenalytixRenalytix (LSE:
RENX) (NASDAQ: RNLX) is the global founder and leader in the new
field of bioprognosis™ for kidney health. The company has
engineered a new solution that enables early-stage chronic kidney
disease progression risk assessment. The Company’s lead product,
KidneyIntelX™, has been granted Breakthrough Designation by the
U.S. Food and Drug Administration and is designed to help make
significant improvements in kidney disease prognosis, transplant
management, clinical care, patient stratification for drug clinical
trials, and drug target discovery (visit www.kidneyintelx.com). For
more information, visit www.renalytix.com.
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Apr 2023 to Apr 2024